University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic

Matthew Herder; E. Richard Gold; Srinivas Murthy

University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic

Matthew Herder
, E. Richard Gold
, Srinivas Murthy

Faculty of Law and Faculty of Medicine, McGill University
Faculty of Medicine, University of British Columbia

Research output: Contribution to journal › Article › peer-review

Abstract

Publicly funded research has contributed enormously to many products that were developed in the face of the COVID-19 pandemic. Yet universities' technology transfer practices have failed to ensure that these products are available in low- and middle-income settings. Drawing upon the example of the lipid nanoparticle delivery technology – which was developed in and around the University of British Columbia in Vancouver, BC, and incorporated into the Pfizer/BioNTech COVID-19 vaccine – we show the divide between the university's stated principles to serve global health and technology transfer in practice. We outline three policy actions to realign universities' technology transfer practices in the service of global health.

Original language	Canadian English
Journal	Healthcare Policy
Volume	17
Issue number	4
Publication status	Published - Jan. 1 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Public Health
Health Care Access
Policy Action
Canada

Disciplines

Food and Drug Law
Health Law and Policy
Intellectual Property Law
Law
Science and Technology Law

Access to Document

https://dal.novanet.ca/permalink/01NOVA_DAL/ev10a8/cdi_proquest_journals_2680335095

Cite this

@article{c29a7a5ba8f343aa9d1b8c0594158157,

title = "University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic",

abstract = " Publicly funded research has contributed enormously to many products that were developed in the face of the COVID-19 pandemic. Yet universities' technology transfer practices have failed to ensure that these products are available in low- and middle-income settings. Drawing upon the example of the lipid nanoparticle delivery technology – which was developed in and around the University of British Columbia in Vancouver, BC, and incorporated into the Pfizer/BioNTech COVID-19 vaccine – we show the divide between the university's stated principles to serve global health and technology transfer in practice. We outline three policy actions to realign universities' technology transfer practices in the service of global health.",

keywords = "COVID-19, Public Health, Health Care Access, Policy Action, Canada",

author = "Matthew Herder and Gold, \{E. Richard\} and Srinivas Murthy",

note = "Matthew Herder, E Richard Gold \& Srinivas Murthy, {"}University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic{"} (2022) 17:4 Healthcare Policy 15.",

year = "2022",

month = jan,

day = "1",

language = "Canadian English",

volume = "17",

number = "4",

}

TY - JOUR

T1 - University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic

AU - Herder, Matthew

AU - Gold, E. Richard

AU - Murthy, Srinivas

N1 - Matthew Herder, E Richard Gold & Srinivas Murthy, "University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic" (2022) 17:4 Healthcare Policy 15.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Publicly funded research has contributed enormously to many products that were developed in the face of the COVID-19 pandemic. Yet universities' technology transfer practices have failed to ensure that these products are available in low- and middle-income settings. Drawing upon the example of the lipid nanoparticle delivery technology – which was developed in and around the University of British Columbia in Vancouver, BC, and incorporated into the Pfizer/BioNTech COVID-19 vaccine – we show the divide between the university's stated principles to serve global health and technology transfer in practice. We outline three policy actions to realign universities' technology transfer practices in the service of global health.

AB - Publicly funded research has contributed enormously to many products that were developed in the face of the COVID-19 pandemic. Yet universities' technology transfer practices have failed to ensure that these products are available in low- and middle-income settings. Drawing upon the example of the lipid nanoparticle delivery technology – which was developed in and around the University of British Columbia in Vancouver, BC, and incorporated into the Pfizer/BioNTech COVID-19 vaccine – we show the divide between the university's stated principles to serve global health and technology transfer in practice. We outline three policy actions to realign universities' technology transfer practices in the service of global health.

KW - COVID-19

KW - Public Health

KW - Health Care Access

KW - Policy Action

KW - Canada

UR - https://digitalcommons.schulichlaw.dal.ca/scholarly_works/1094

UR - https://dal.novanet.ca/permalink/01NOVA_DAL/ev10a8/cdi_proquest_journals_2680335095

M3 - Article

SN - 1715-6572

VL - 17

JO - Healthcare Policy

JF - Healthcare Policy

IS - 4

ER -

University Technology Transfer Has Failed to Improve Access to Global Health Products During the COVID-19 Pandemic

Abstract

UN SDGs

Keywords

Disciplines

Access to Document

Other files and links

Fingerprint

Cite this